title: Passive immunization with LINGO-1 polyclonal antiserum afforded neuroprotection and promoted functional recovery in a rat model of spinal cord injury.
abstract: LINGO-1 (leucine-rich repeat and Ig domain-containing, Nogo receptor-interacting protein) is an important component of the NgR receptor complex involved in RhoA activation and axon regeneration. The authors report on passive immunization with LINGO-1 polyclonal antiserum, a therapeutic approach to overcome NgR-mediated growth inhibition after spinal cord injury (SCI). The intrathecally administered high-titer rabbit-derived antiserum can be detected around the injury site within a wide time window; it blocks LINGO-1 in vivo with high molecular specificity. In this animal model, passive immunization with LINGO-1 antiserum significantly decreased RhoA activation and increased neuronal survival. Adult rats immunized in this manner show recovery of certain hindlimb motor functions after dorsal hemisection of the spinal cord. Thus, passive immunotherapy with LINGO-1 polyclonal antiserum may represent a promising repair strategy following acute SCI.
authors.affiliation: Department of Neurosurgery, Neurosurgery Institute of Guangdong, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Lv
authors.forename: Ru-xiang
authors.initials: RX
authors.lastname: Xu
authors.forename: Xiao-dan
authors.initials: XD
authors.lastname: Jiang
authors.forename: Xin
authors.initials: X
authors.lastname: Lu
authors.forename: Yi-quan
authors.initials: YQ
authors.lastname: Ke
authors.forename: Ying-qian
authors.initials: YQ
authors.lastname: Cai
authors.forename: Mou-xuan
authors.initials: MX
authors.lastname: Du
authors.forename: Changchen
authors.initials: C
authors.lastname: Hu
authors.forename: Yu-xi
authors.initials: YX
authors.lastname: Zou
authors.forename: Ling-sha
authors.initials: LS
authors.lastname: Qin
authors.forename: Yan-jun
authors.initials: YJ
authors.lastname: Zeng
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D019610:Cytoprotection / Q000187:drug effects* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D007106:Immune Sera / Q000276:immunology / Q000494:pharmacology; D007116:Immunization, Passive / Q000379:methods*; D007278:Injections, Spinal; D008565:Membrane Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D009410:Nerve Degeneration / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D010243:Paralysis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects* / Q000276:immunology; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016896:Treatment Outcome; D020742:rhoA GTP-Binding Protein / Q000187:drug effects / Q000378:metabolism
chemical_list: D007106:Immune Sera; C525164:LINGO1 protein, rat; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D020742:rhoA GTP-Binding Protein